CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2700 · Search date 2026-08-15 · Methodology v0.7

Comfrey root extract ointment,
does it really help with Reduced acute nonspecific upper or lower back pain?

30-Second Summary
C
Evidence Grade C · 46 · Safety caution
Comfrey root extract ointment reduced acute back pain, but evidence is one manufacturer-sponsored trial
Use a topical product reduced in pyrrolizidine alkaloids for a short course as studied. Avoid broken skin, pregnancy, breastfeeding, prolonged or extensive application, and do not ingest comfrey.
What the
research shows
The grade is C with 46 points. In a 120-person randomized trial, movement pain fell from 104.8 to 12.7 mm with comfrey and from 100.0 to 56.5 mm with placebo; the primary AUC difference had P<0.0001. Evidence is one 120-person trial sponsored by manufacturer Merck Selbstmedikation, with no reported implementation method for allocation concealment.
What the
ads claim
The tested product was not any comfrey salve. It contained 35 g of a specified comfrey-root fluid extract per 100 g and was reduced in pyrrolizidine alkaloids. The result does not extend to homemade comfrey, leaf products, or oral ingestion.
*

Useful facts when choosing a product

  • Participants applied 4 g of Kytta-Salbe f three times daily for 5±1 days.
  • Each 100 g contained 35 g of comfrey-root fluid extract, and the test product was reduced in pyrrolizidine alkaloids.
  • EudraCT 2006-003621-87 identifies the trial report and the same study as the paper.
Gap Measurement · Verdict 2700 · C 46
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Four German centers randomized 120 participants equally to comfrey or appearance-matched placebo; all 120 were included in ITT/full analysis. The primary endpoint was AUC of standardized-movement VAS over four visits and matched the trial report. Public reporting did not reveal sequence generation or practical allocation concealment, and the trial was smaller than 200. Five-day follow-up fits the natural course of acute pain and was not separately counted as a short-duration flaw. The trial report names Merck Selbstmedikation GmbH as sponsor, and the second author was affiliated with the company.

02

Why this is classified as C (46)

The pain difference was significant but its magnitude cannot be judged; one 120-person manufacturer-sponsored trial with unreported concealment implementation gives C with 46 points.

Counterpoint. Broken skin, pregnancy, breastfeeding, prolonged or extensive use require safety review, and oral comfrey should not be confused with this topical product.

Rejudgment record. Cross-check applied — Cross-checked the article and EudraCT clinical trial report for the primary VAS AUC, all-120 analysis, sponsor and author affiliation, allocation reporting, and product composition

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeEXThe clinical size of the effect could not be judged
PrecisionCXNo pooled confidence interval could be confirmed

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Comfrey root extract ointment reduces acute nonspecific back painCThe primary VAS AUC difference had P<0.0001.
Oral comfrey provides the same benefit?The trial evaluated only a topical ointment reduced in pyrrolizidine alkaloids.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Giannetti BM, Staiger C, Bulitta M, Predel HG. 2010Four-center randomized double-blind placebo-ointment-controlled trial118Sponsored by Merck Selbstmedikation GmbH; second author affiliated with the manufacturerAUC of VAS pain during standardized movement over four visitsSummed VAS 104.8 to 12.7 mm versus 100.0 to 56.5 mm; primary AUC P<0.0001; adjusted between-group difference and variance not reportedSmall single positive manufacturer-sponsored trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-15).

Giannetti BM, Staiger C, Bulitta M, Predel HG. Efficacy and safety of comfrey root extract ointment in the treatment of acute upper or lower back pain: results of a double-blind, randomised, placebo controlled, multicentre trial. Br J Sports Med. 2010;44(9):637-641. PMID: 19460762. DOI: 10.1136/bjsm.2009.058677. EudraCT 2006-003621-87.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Comfrey root extract ointment x acute back pain Evidence Grade C card
[Chamgap] Comfrey root extract ointment x acute back pain — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/comfrey-root-extract-ointment-acute-back-pain/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.